IPO grey market premium explained: why GMP often misleads retail investors

Every time a popular IPO opens for subscription, one number dominates WhatsApp groups and social feeds: the grey market premium, or GMP. If the GMP is high, the issue is "hot". If it is falling, investors panic. For something so widely followed, few people understand what the number actually is — or how often it has led retail investors into poor decisions.

Our view at TrendRipperX is simple: GMP is a sentiment gauge, not a valuation tool. It can tell you how excited a small group of traders is on a given afternoon. It cannot tell you whether a business is worth owning.

What the grey market actually is

The grey market is an informal, unregulated space where IPO shares are bought and sold before they list on the exchange. No exchange runs it, SEBI does not recognise it, and there is no clearing house guaranteeing that a trade will be honoured. Deals happen through networks of dealers, usually settled in cash or on trust, and are completed only once the shares list.

The premium is the amount above the issue price at which these dealers say they are willing to buy. If an IPO is priced at a level the market likes, a dealer might offer a premium on the expectation that the stock will list higher. That quoted premium is the GMP you see on websites.

There is also the "kostak" or "subject to sauda" rate, where traders buy a retail application itself — before allotment is known — for a fixed amount. These rates follow the same logic and carry the same weaknesses.

Why the number is so fragile

The first problem is volume. The grey market is thin. A handful of trades, or even a few quoted bids, can move the GMP sharply. A number that sounds authoritative may rest on very little money changing hands.

The second problem is incentive. People who benefit from heavy subscription — intermediaries, distributors, and traders who have applied in bulk — also benefit when the GMP looks attractive. Nothing prevents anyone from talking a premium up. We are not saying every GMP is manipulated; we are saying there is no mechanism to stop it.

The third problem is timing. GMP forecasts one thing only: the opening price on listing day. Even on that narrow question it is frequently wrong. A broad sell-off in the week of listing can wipe out a premium that looked safe days earlier.

The deeper mistake: confusing listing day with investing

Suppose, for illustration, an IPO is priced at ₹100 and quoted at a GMP of ₹40. Many investors read that as "40% free money". Even if the stock lists at ₹140, the more important question is what happens over the next three years. Plenty of Indian IPOs have listed at a premium and then traded below their issue price for long stretches, because the IPO valuation already priced in years of growth.

A business does not become better because demand for its shares was high in the grey market. Its long-term return depends on profit growth, the price you paid, and how well management allocates capital. None of those appear in the GMP.

What to read instead of GMP

The offer document — the red herring prospectus — contains almost everything you need. It is long, but most of the value sits in a few sections.

• Objects of the issue: Is the company raising fresh money to grow, or are existing shareholders selling through an offer for sale? If it is mostly an offer for sale, the money goes to sellers, not the business.
• Financial statements: Look at three years of revenue, operating profit and cash flow from operations. Profit that does not turn into cash is a warning sign.
• Debt: Rising borrowings ahead of an IPO deserve a question.
• Valuation against listed peers: If the IPO is priced at a much richer multiple than established competitors, ask why.
• Risk factors: This is where the company itself tells you what can go wrong.

Subscription data also says more than GMP. Demand from qualified institutional buyers reflects professional analysis; retail oversubscription mostly reflects excitement.

Common mistakes we see

• Applying through several family accounts purely because GMP is high, without reading anything about the company.
• Holding after listing "because it listed well", with no long-term plan.
• Selling a sound business on listing day because the GMP promised more than the market delivered.
• Treating a falling GMP as proof that a company is bad, when the market may simply be weak that week.

Why this matters to you

If you are a long-term investor, GMP should be close to irrelevant. Decide whether you would happily own the company at the issue price for five years. If yes, apply; if not, skip it regardless of the premium.

If you are applying for listing gains, be honest that it is a short-term trade with uncertain odds. Decide in advance what you will do on listing day — sell at the open, sell at a set price, or hold — and stick to it. Allotment in popular issues is a lottery, so do not stretch your finances chasing it.

The TrendRipperX view

GMP is popular because it is easy: one number, updated daily, that seems to answer a complicated question. Investing does not reward easy answers. Use GMP the way you would use a weather report before a picnic — a hint about mood — and do the real work in the prospectus. Follow live premiums on our IPO GMP page, but read them alongside the fundamentals, never instead of them.